Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAM4083
- Development stage
- Preclinical
- Lead developer
- Camurus
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
CAM4083 is a long-acting, weekly subcutaneous depot formulation of the complement component 5 (C5) inhibitor zilucoplan, developed using Camurus’ FluidCrystal technology as a sustained-release version of zilucoplan for chronic administration. It is being developed in partnership with UCB (originally Ra Pharmaceuticals) for the treatment of generalized myasthenia gravis, immune‑mediated necrotizing myopathy, and other tissue‑based complement C5‑mediated disorders, aiming to provide convenient once‑weekly dosing with maintained C5 inhibition for diseases driven by terminal complement pathway activation.[1][9][7][13]
02
Targets
C5
Beyond the preview
Go deeper on CAM4083.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAM4083.